Mark Wong
Mississauga, ON L5L1J9, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.
Journal: Frontiers in immunology
Published: October 28, 2024
Effectiveness of population-based recovery actions for threatened southern mountain caribou.
Journal: Ecological applications : a publication of the Ecological Society of America
Published: July 10, 2023
Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides.
Journal: Cancers
Published: October 30, 2021
The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.
Journal: Cancer immunology, immunotherapy : CII
Published: May 11, 2021
Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
Journal: British journal of haematology
Published: August 02, 2020
SIRPαFc treatment targets human acute myeloid leukemia stem cells.
Journal: Haematologica
Published: February 13, 2020
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma.
Journal: Nature medicine
Published: November 21, 2019
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Journal: PloS one
Published: March 15, 2017
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 05, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026